Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients.

COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Carlo J Iasella, Stefanie J Hannan, Emily J Lyons, Sophia C Lieber, Antu Das, Dimiter Dimitrov, Wei Li, Melissa Saul, Iulia Popescu, Ritchie Koshy, Robin Burke, Braidon Lape, Mark J Brown, Xiaoping Chen, John C Sembrat, Kaitlyn Devonshire, Georgios D Kitsios, Ioannis Konstantinidis, Mark E Snyder, Bill B Chen, Christian A Merlo, David N Hager, Joseph E Kiss, Mark H Yazer, Alan H Wells, Alison Morris, Bryan J McVerry, Deborah K McMahon, Darrell J Triulzi, John F McDyer
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0309449
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients.

Similar Items